Lilly and Bristol's cancer drug Erbitux gets expanded FDA approval

11/7/2011 | Wall Street Journal, The

The FDA authorized the use of Erbitux with chemotherapy for patients with advanced neck and head cancer. Erbitux, marketed by Bristol-Myers Squibb and Eli Lilly and Co., also treats nonmetastatic cases as well as certain types of bowel cancer.

View Full Article in:

Wall Street Journal, The

Published in Briefs: